Nuveen’s Oscar Health OSCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$50.5M Buy
1,770,745
+446,444
+34% +$9.61M 0.01% 702
2026
Q1
$15.2M Buy
1,324,301
+139,192
+12% +$1.96M ﹤0.01% 1300
2025
Q4
$17M Buy
1,185,109
+338,998
+40% +$5.86M ﹤0.01% 1236
2025
Q3
$16M Sell
846,111
-969,078
-53% -$16M ﹤0.01% 1273
2025
Q2
$38.9M Sell
1,815,189
-449,009
-20% -$6.68M 0.01% 717
2025
Q1
$29.7M Sell
2,264,198
-92,100
-4% -$1.37M 0.01% 881
2024
Q4
$31.7M Buy
2,356,298
+23,237
+1% +$374K 0.01% 882
2024
Q3
$49.5M Sell
2,333,061
-11,574
-0.5% -$208K 0.01% 662
2024
Q2
$37.1M Buy
2,344,635
+35,008
+2% +$643K 0.01% 769
2024
Q1
$34.3M Buy
2,309,627
+5,799
+0.3% +$79.4K 0.01% 833
2023
Q4
$21.1M Buy
2,303,828
+60,102
+3% +$415K 0.01% 1126
2023
Q3
$12.5M Buy
2,243,726
+433,735
+24% +$3.04M ﹤0.01% 1343
2023
Q2
$14.6M Buy
1,809,991
+652,011
+56% +$4.81M 0.01% 1282
2023
Q1
$7.57M Sell
1,157,980
-55,607
-5% -$227K ﹤0.01% 1651
2022
Q4
$2.98M Buy
1,213,587
+580,220
+92% +$1.81M ﹤0.01% 2198
2022
Q3
$3.16M Buy
633,367
+211,859
+50% +$1.24M ﹤0.01% 2154
2022
Q2
$1.79M Buy
+421,508
New +$2.68M ﹤0.01% 2488

Other funds holding OSCR

Nuveen's OSCR Position: Q2 2026 in Review

Nuveen increased its Oscar Health (OSCR) stake by 34% in Q2 2026, buying an estimated $9.61M and bringing the position to 1,770,745 shares worth $50.5M. The position accounts for 0.01% of the portfolio, ranked #702.

Nuveen first reported a position in OSCR in Q2 2022 and has held it in 17 quarters since. 403 funds tracked by Wall St. Rank hold OSCR as of Q2 2026.

  • Nuveen held 1,770,745 shares of Oscar Health worth $50.5M as of Q2 2026.
  • Nuveen bought 446,444 Oscar Health shares in Q2 2026, an estimated $9.61M.
  • Oscar Health made up 0.01% of Nuveen's portfolio in Q2 2026, its #702 holding.
  • Nuveen first reported a position in Oscar Health in Q2 2022 and has held it in 17 quarters since.
  • 403 funds tracked by Wall St. Rank held Oscar Health as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.